Published January 1, 2022
| Version v1
Journal article
Open
Context dependent isoform specific PI3K inhibition confers drug resistance in hepatocellular carcinoma cells
Creators
- 1. Middle East Tech Univ, Grad Sch Informat, Canc Syst Biol Lab, CanSyL, TR-06800 Ankara, Turkey
Description
Background: Targeted therapies for Primary liver cancer (HCC) is limited to the multi-kinase inhibitors, and not fully effective due to the resistance to these agents because of the heterogeneous molecular nature of HCC developed during chronic liver disease stages and cirrhosis. Although combinatorial therapy can increase the efficiency of targeted therapies through synergistic activities, isoform specific effects of the inhibitors are usually ignored. This study concentrated on PI3K/Akt/mTOR pathway and the differential combinatory bioactivities of isoform specific PI3K-alpha inhibitor (PIK-75) or PI3K-beta inhibitor (TGX-221) with Sorafenib dependent on PTEN context.
Files
bib-3100186c-ef53-494e-9048-d0a25518c0fc.txt
Files
(210 Bytes)
| Name | Size | Download all |
|---|---|---|
|
md5:e2757e177ebae37249a41eaa14d16415
|
210 Bytes | Preview Download |